Atlas Venture Life Science Advisors, LLC Q4 2023 Filing
Filed February 9, 2024
Portfolio Value
$839.8B
Holdings
16
Report Date
Q4 2023
Filing Type
13F-HR
All Holdings (16 positions)
| # | Stock | Shares | Value | % Portfolio | Type |
|---|---|---|---|---|---|
| 1 | KYMRKymera Therapeutics, Inc. | 5,858,262 | $149.2B | 17.76% | |
| 2 | IRONDisc Medicine, Inc. | 2,555,172 | $147.6B | 17.58% | |
| 3 | DYNDyne Therapeutics, Inc. | 9,885,449 | $131.5B | 15.66% | |
| 4 | THRDThird Harmonic Bio, Inc. | 10,907,859 | $119.7B | 14.25% | |
| 5 | DAWNDay One Biopharmaceuticals, Inc. | 7,608,394 | $111.1B | 13.23% | |
| 6 | KRROKorro Bio, Inc. | 1,119,292 | $53.6B | 6.39% | |
| 7 | AVTEAerovate Therapeutics, Inc. | 2,039,249 | $46.1B | 5.50% | |
| 8 | VIGLVigil Neuroscience, Inc. | 5,836,874 | $19.7B | 2.35% | |
| 9 | REPLReplimune Group, Inc. | 2,098,300 | $17.7B | 2.11% | |
| 10 | GBIOGBXGeneration Bio, Co. | 8,279,484 | $13.7B | 1.63% | |
| 11 | —Ikena Oncology, Inc. | 5,018,178 | $9.9B | 1.18% | |
| 12 | AKROAkero Therapeutics, Inc. | 359,251 | $8.4B | 1.00% | |
| 13 | —AvroBio, Inc. | 4,541,381 | $6.2B | 0.74% | |
| 14 | DNTHDianthus Therapeutics, Inc. | 236,979 | $2.5B | 0.29% | |
| 15 | XLOXilio Therapeutics, Inc. | 2,759,344 | $1.5B | 0.18% | |
| 16 | SPROSpero Therapeutics, Inc. | 1,013,438 | $1.5B | 0.18% |